RELATED CONTENT
NEWS
- BioSante to begin Phase I trial of melanoma vaccine at Johns Hopkins
- Focus on Almirall: partnering, new products and mature markets are key targets
- Austerity takes off gloss from Basilea's Toctino forecasts
- Tesaro's $101 million series B to fund rolapitant PhIII and build oncology portfolio

